Yazar "Altunrende, Burcu" seçeneğine göre listele

Listeleniyor 1 - 3 / 3
  • Küçük Resim
    Öğe
    Fingolimod for the treatment of relapsing-remitting multiple sclerosis
    (Turkish Neurological Society, 2017) Altunrende, Burcu; Birday, Erkingül; Kasap, Mithat; Akman Demir, Gülşen
    Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system and is characterized by inflammation, demyelination, and axonal loss. Fingolimod is the first oral drug for the treatment of MS approved by the United States Food and Drug Administration, European Union countries, and various other countries. The compound exerts its effect via interaction with lysophospholipid receptors known as sphingosine-1 phosphate receptors. Although fingolimod has a very convenient daily oral dosing, it may cause development of bradycardia at the first dose, macular edema, infection, all of which require attention. Randomized double-blind clinical trials have shown that fingolimod significantly reduces relapse rates and is beneficial in brain magnetic resonance imaging measures when compared with both placebo and intramuscular interferon beta-1a. This review describes the characteristics of fingolimod concerning its efficacy, safety, and tolerability in the clinical context of the management of MS.
  • Küçük Resim Yok
    Öğe
    Neuromyelitis optica and neuromyelitis optica spectrum disorders: the evaluation of 86 patients followed by Istanbul Bilim University
    (Sage Publications Ltd., 2014) Altunrende, Burcu; Tavlı, Ahmet Mithat; Altınkaya, Ayça; Topçular, Barış; Kocarslan, Meryem; Server, Sadık; Fırtına, Sinem; Yenice, Sedef; Akman Demir, Gülsen
    [Abstract Not Available]
  • Küçük Resim
    Öğe
    Neuromyelitis optica and neuromyelitis optica spectrum disorders: The evaluation of 86 patients followed by Istanbul Bilim University, department of neurology
    (Sage PubLlications, 2015) Altunrende, Burcu; Tavlı, Ahmet Mithat; Altınkaya, Ayça; Topçular, Barış; Kocarslan, Meryem; Server, Sadık; Fırtına, Sinem; Yenice, Sedef; Akman Demir, Gülsen
    Background and objectives: Neuromyelitis optica (NMO) and its spectrum disorders (NMOSD) are relatively rare disorders. We aimed to evaluate clinical characteristics and disease course of the NMOSD patients followed at our department. Patients and methods: All the patients with the diagnosis of NMO/ NMOSD followed since the establishment of our multipl sclerosis clinic in April 2011, were evaluated. Results: There were 86 patients (66 female, 20 male) with NMO/ NMOSD followed at our MS unit; 24 had NMO, 42 had recurrent optic neuritis (RON); and 20 had longitudinally extensive transverse myelitis (LETM). The disease course was relapsing in 70 patients e296 Abstracts / Journal of the Neurological Sciences 357 (2015) e295–e323 (81%). The first attack was bilateral ON (BON) and TM in 3 patients, ON and TM in 1 patient, ON in 50 patients (bilateral in 6) and TM in 26 patients. NMO IgG was positive in 12 patients with NMO (55%), 4 patients with LETM (25%), and 8 patients with RON (25%). Oligoclonal band was positive in 15 out of 44 patients (34%). In NMO/NMOSD patients, cranial magnetic resonance imaging (MRI) showed no abnormality in 48; nonspecific lesions in 37; and 1 patient had hypothalamic lesion. In spinal MRIs, 41 patients had LETM; six had suspected hyperintense T2 lesion in C5. Conclusion: This is one of the largest single center series collected over 4 years. NMO/NMOSD seems to be over-represented in our center since it is one of the few where NMO IgG testing is available. In NMO/NMOSD, early diagnosis and treatment is important to prevent the patient from the permanent disability.